These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 34431421)

  • 21. Long-term contraception with the levonorgestrel 20 mcg/day (LNg 20) and the copper T 380Ag intrauterine devices: a five-year randomized study.
    Sivin I; el Mahgoub S; McCarthy T; Mishell DR; Shoupe D; Alvarez F; Brache V; Jimenez E; Diaz J; Faundes A
    Contraception; 1990 Oct; 42(4):361-78. PubMed ID: 2124179
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Continuation and satisfaction of reversible contraception.
    Peipert JF; Zhao Q; Allsworth JE; Petrosky E; Madden T; Eisenberg D; Secura G
    Obstet Gynecol; 2011 May; 117(5):1105-1113. PubMed ID: 21508749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in body composition in women using long-acting reversible contraception.
    Silva Dos Santos PN; Madden T; Omvig K; Peipert JF
    Contraception; 2017 Apr; 95(4):382-389. PubMed ID: 28041992
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Two years of intrauterine contraception with levonorgestrel and with copper: a randomized comparison of the TCu 380Ag and levonorgestrel 20 mcg/day devices.
    Sivin I; Stern J; Diaz J; Diaz MM; Faundes A; el Mahgoub S; Diaz S; Pavez M; Coutinho E; Mattos CE
    Contraception; 1987 Mar; 35(3):245-55. PubMed ID: 3111785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-acting reversible contraceptive acceptability and unintended pregnancy among women presenting for short-acting methods: a randomized patient preference trial.
    Hubacher D; Spector H; Monteith C; Chen PL; Hart C
    Am J Obstet Gynecol; 2017 Feb; 216(2):101-109. PubMed ID: 27662799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intrauterine Contraception Continuation in Adolescents and Young Women: A Systematic Review.
    Usinger KM; Gola SB; Weis M; Smaldone A
    J Pediatr Adolesc Gynecol; 2016 Dec; 29(6):659-667. PubMed ID: 27386754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
    Dominick S; Hickey M; Chin J; Su HI
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007245. PubMed ID: 26649916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differences in continuation rates and early removal between contraceptive and therapeutic use of the levonorgestrel-releasing intrauterine system 52 mg.
    Teunissen AM; Merry AHH; Devies IEC; Roumen FJME
    Eur J Contracept Reprod Health Care; 2019 Dec; 24(6):449-456. PubMed ID: 31696740
    [No Abstract]   [Full Text] [Related]  

  • 29. Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices.
    Sivin I; Stern J; Diaz S; Pavéz M; Alvarez F; Brache V; Mishell DR; Lacarra M; McCarthy T; Holma P
    Am J Obstet Gynecol; 1992 Apr; 166(4):1208-13. PubMed ID: 1566771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Twenty-four-month continuation of reversible contraception.
    O'Neil-Callahan M; Peipert JF; Zhao Q; Madden T; Secura G
    Obstet Gynecol; 2013 Nov; 122(5):1083-1091. PubMed ID: 24104781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effective contraception with the levonorgestrel-releasing intrauterine device: 12-month report of a European multicenter study.
    Luukkainen T; Allonen H; Haukkamaa M; Holma P; Pyörälä T; Terho J; Toivonen J; Batar I; Lampe L; Andersson K
    Contraception; 1987 Aug; 36(2):169-79. PubMed ID: 3123132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Levonorgestrel-releasing intrauterine system and breast cancer risk: A systematic review and meta-analysis.
    Conz L; Mota BS; Bahamondes L; Teixeira Dória M; Françoise Mauricette Derchain S; Rieira R; Sarian LO
    Acta Obstet Gynecol Scand; 2020 Aug; 99(8):970-982. PubMed ID: 31990981
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immediate versus delayed initiation of the levonorgestrel-releasing intrauterine system following medical termination of pregnancy - 1 year continuation rates: a randomised controlled trial.
    Korjamo R; Mentula M; Heikinheimo O
    BJOG; 2017 Dec; 124(13):1957-1964. PubMed ID: 28650566
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial.
    Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium
    Lancet; 2019 Jul; 394(10195):303-313. PubMed ID: 31204114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.
    Lethaby A; Hussain M; Rishworth JR; Rees MC
    Cochrane Database Syst Rev; 2015 Apr; (4):CD002126. PubMed ID: 25924648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
    Sturridge F; Guillebaud J
    Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pregnancy outcomes associated with extended use of the 52-mg 20 μg/day levonorgestrel-releasing intrauterine system beyond 60 months: A chart review of 776 women in Brazil.
    Bahamondes L; Fernandes A; Bahamondes MV; Juliato CT; Ali M; Monteiro I
    Contraception; 2018 Mar; 97(3):205-209. PubMed ID: 29055780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intrauterine device continuation rates and reasons for discontinuation in a Central European clinic with a high standard of care and ultrasound follow-up: a retrospective cohort study.
    Bachofner M; Blickenstorfer K; Hutmacher J; Wehrle L; Leeners B; Merki-Feld G
    Eur J Contracept Reprod Health Care; 2018 Dec; 23(6):407-414. PubMed ID: 30628516
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Levonorgestrel-releasing (20 microgram/day) intrauterine systems (Mirena) compared with other methods of reversible contraceptives.
    French RS; Cowan FM; Mansour D; Higgins JP; Robinson A; Procter T; Morris S; Guillebaud J
    BJOG; 2000 Oct; 107(10):1218-25. PubMed ID: 11028571
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness analysis of levonorgestrel-releasing intrauterine system (LNG-IUS) 13.5 mg in contraception.
    Trussell J; Hassan F; Henry N; Pocoski J; Law A; Filonenko A
    Contraception; 2014 May; 89(5):451-9. PubMed ID: 24576791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.